Baseline Demographic and Clinical Characteristics of the Study Cohort (n = 675)
| Characteristic | No. (%)* |
| Sex | |
| Male | 320 (47.4) |
| Female | 355 (52.6) |
| Age, y, median (range) | 36.1 (18.5–80.8) |
| Weight, kg, median (range) | 53 (30–104) |
| Receiving ART | 252 (37.3) |
| HIV-VL, copies/mL, median (range) | 104 252 (29–1 × 107) |
| CD4 count, cells/μL, median (range) | 62 (0–526) |
| Patients with anemia | 622 (92.1) |
| Hemoglobin, g/dL, median (range) | 8.9 (3.9–17.4) |
| Patients with detectable IL-6 | 559 (82.8) |
| IL-6 concentration, pg/mL, median (IQR) | 42.3 (9.8–103.8) |
| TB/infection category | |
| Patients with proven TB | 500 (74.1) |
| Patients with an alternate microbiologically proven OI | 16 (2.4) |
| Patients without microbiologically proven TB or other coinfections | 159 (23.5) |
| KSHV status in patients | |
| Seropositive | 207 (30.7) |
| Seropositive with detectable VL | 39 (5.8) |
| Seropositive with detectable VL, copies/106 cells, median (range) | 199.05 (13.4–2.2 × 106) |
| Seropositive with elevated VL (>100 copies/106 cells) | 29 (4.3) |
| Seronegative | 468 (69.3) |
| Seronegative with detectable VL | 4 (0.6) |
| Seronegative with detectable VL, copies/106 cells, median (range) | 1084.29 (141.4–57 054) |
| Seronegative with elevated VL (>100 copies/106 cells) | 4 (0.6) |
| Skin or oral Kaposi’s sarcoma | 10 (1.5) |
| Confirmed vital status at 12 wk | |
| Lost to follow-up | 12 (1.8) |
| Survived | 517 (76.6) |
| Died | 146 (21.6) |
| Characteristic | No. (%)* |
| Sex | |
| Male | 320 (47.4) |
| Female | 355 (52.6) |
| Age, y, median (range) | 36.1 (18.5–80.8) |
| Weight, kg, median (range) | 53 (30–104) |
| Receiving ART | 252 (37.3) |
| HIV-VL, copies/mL, median (range) | 104 252 (29–1 × 107) |
| CD4 count, cells/μL, median (range) | 62 (0–526) |
| Patients with anemia | 622 (92.1) |
| Hemoglobin, g/dL, median (range) | 8.9 (3.9–17.4) |
| Patients with detectable IL-6 | 559 (82.8) |
| IL-6 concentration, pg/mL, median (IQR) | 42.3 (9.8–103.8) |
| TB/infection category | |
| Patients with proven TB | 500 (74.1) |
| Patients with an alternate microbiologically proven OI | 16 (2.4) |
| Patients without microbiologically proven TB or other coinfections | 159 (23.5) |
| KSHV status in patients | |
| Seropositive | 207 (30.7) |
| Seropositive with detectable VL | 39 (5.8) |
| Seropositive with detectable VL, copies/106 cells, median (range) | 199.05 (13.4–2.2 × 106) |
| Seropositive with elevated VL (>100 copies/106 cells) | 29 (4.3) |
| Seronegative | 468 (69.3) |
| Seronegative with detectable VL | 4 (0.6) |
| Seronegative with detectable VL, copies/106 cells, median (range) | 1084.29 (141.4–57 054) |
| Seronegative with elevated VL (>100 copies/106 cells) | 4 (0.6) |
| Skin or oral Kaposi’s sarcoma | 10 (1.5) |
| Confirmed vital status at 12 wk | |
| Lost to follow-up | 12 (1.8) |
| Survived | 517 (76.6) |
| Died | 146 (21.6) |
*Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IL-6, interleukin 6; IQR, interquartile range; KSHV, Kaposi’s sarcoma–associated herpesvirus; OI, opportunistic infection; TB, tuberculosis; VL, viral load.
Baseline Demographic and Clinical Characteristics of the Study Cohort (n = 675)
| Characteristic | No. (%)* |
| Sex | |
| Male | 320 (47.4) |
| Female | 355 (52.6) |
| Age, y, median (range) | 36.1 (18.5–80.8) |
| Weight, kg, median (range) | 53 (30–104) |
| Receiving ART | 252 (37.3) |
| HIV-VL, copies/mL, median (range) | 104 252 (29–1 × 107) |
| CD4 count, cells/μL, median (range) | 62 (0–526) |
| Patients with anemia | 622 (92.1) |
| Hemoglobin, g/dL, median (range) | 8.9 (3.9–17.4) |
| Patients with detectable IL-6 | 559 (82.8) |
| IL-6 concentration, pg/mL, median (IQR) | 42.3 (9.8–103.8) |
| TB/infection category | |
| Patients with proven TB | 500 (74.1) |
| Patients with an alternate microbiologically proven OI | 16 (2.4) |
| Patients without microbiologically proven TB or other coinfections | 159 (23.5) |
| KSHV status in patients | |
| Seropositive | 207 (30.7) |
| Seropositive with detectable VL | 39 (5.8) |
| Seropositive with detectable VL, copies/106 cells, median (range) | 199.05 (13.4–2.2 × 106) |
| Seropositive with elevated VL (>100 copies/106 cells) | 29 (4.3) |
| Seronegative | 468 (69.3) |
| Seronegative with detectable VL | 4 (0.6) |
| Seronegative with detectable VL, copies/106 cells, median (range) | 1084.29 (141.4–57 054) |
| Seronegative with elevated VL (>100 copies/106 cells) | 4 (0.6) |
| Skin or oral Kaposi’s sarcoma | 10 (1.5) |
| Confirmed vital status at 12 wk | |
| Lost to follow-up | 12 (1.8) |
| Survived | 517 (76.6) |
| Died | 146 (21.6) |
| Characteristic | No. (%)* |
| Sex | |
| Male | 320 (47.4) |
| Female | 355 (52.6) |
| Age, y, median (range) | 36.1 (18.5–80.8) |
| Weight, kg, median (range) | 53 (30–104) |
| Receiving ART | 252 (37.3) |
| HIV-VL, copies/mL, median (range) | 104 252 (29–1 × 107) |
| CD4 count, cells/μL, median (range) | 62 (0–526) |
| Patients with anemia | 622 (92.1) |
| Hemoglobin, g/dL, median (range) | 8.9 (3.9–17.4) |
| Patients with detectable IL-6 | 559 (82.8) |
| IL-6 concentration, pg/mL, median (IQR) | 42.3 (9.8–103.8) |
| TB/infection category | |
| Patients with proven TB | 500 (74.1) |
| Patients with an alternate microbiologically proven OI | 16 (2.4) |
| Patients without microbiologically proven TB or other coinfections | 159 (23.5) |
| KSHV status in patients | |
| Seropositive | 207 (30.7) |
| Seropositive with detectable VL | 39 (5.8) |
| Seropositive with detectable VL, copies/106 cells, median (range) | 199.05 (13.4–2.2 × 106) |
| Seropositive with elevated VL (>100 copies/106 cells) | 29 (4.3) |
| Seronegative | 468 (69.3) |
| Seronegative with detectable VL | 4 (0.6) |
| Seronegative with detectable VL, copies/106 cells, median (range) | 1084.29 (141.4–57 054) |
| Seronegative with elevated VL (>100 copies/106 cells) | 4 (0.6) |
| Skin or oral Kaposi’s sarcoma | 10 (1.5) |
| Confirmed vital status at 12 wk | |
| Lost to follow-up | 12 (1.8) |
| Survived | 517 (76.6) |
| Died | 146 (21.6) |
*Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IL-6, interleukin 6; IQR, interquartile range; KSHV, Kaposi’s sarcoma–associated herpesvirus; OI, opportunistic infection; TB, tuberculosis; VL, viral load.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
